CSPC Pharmaceutical Group Limited CSPCY
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 90.93% | 8.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 90.93% | 8.22% | |||
| Cost of Revenue | 3.62% | 6.82% | |||
| Gross Profit | 135.88% | 8.96% | |||
| SG&A Expenses | 1.51% | 3.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.57% | 0.37% | |||
| Operating Income | 566.64% | 93.66% | |||
| Income Before Tax | 474.11% | 129.52% | |||
| Income Tax Expenses | 245.47% | 50.31% | |||
| Earnings from Continuing Operations | 536.57% | 168.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -1,011.95% | -202.09% | |||
| Net Income | 519.60% | 137.39% | |||
| EBIT | 566.64% | 93.66% | |||
| EBITDA | 438.33% | 60.95% | |||
| EPS Basic | 519.27% | 136.96% | |||
| Normalized Basic EPS | 444.19% | 377.78% | |||
| EPS Diluted | 517.43% | 136.96% | |||
| Normalized Diluted EPS | 443.02% | 377.78% | |||
| Average Basic Shares Outstanding | -0.03% | -0.01% | |||
| Average Diluted Shares Outstanding | 0.30% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||